Centocor gets rights to DDDP's thrombin inhibitors

Centocor, a subsidiary of Johnson & Johnson (JNJ), acquired worldwide rights to 3-Dimensional's orally active direct thrombin inhibitor program including its lead product 3DP-4815, which is in Phase I...